Other FDA Approved

Romidepsin

A bicyclic depsipeptide histone deacetylase inhibitor from Chromobacterium violaceum, approved by the FDA in 2009 as Istodax for cutaneous T-cell lymphoma; its 2011 accelerated approval for peripheral T-cell lymphoma was removed in 2021 after Ro-CHOP failed.

HDAC InhibitorCutaneous T-cell LymphomaDepsipeptideOncologyFDA Approved

Also referenced as: FK228, FR901228, FR 901228, NSC 630176, Istodax

Also appears in: Immune

Public product evidence No certificate records are bound to a tracked Romidepsin product page A record counts here only when a vendor publishes a certificate against one of its own tracked Romidepsin product pages. Other certificates naming this compound may still exist — search the wider certificate database.
Status
FDA Approved

This compound maps to at least one regulated medical product or label context in the United States.

Research area
Other research areas

Primary research area: Other. Also surfaces under Immune for browsing and discovery.

Body systems
Immune · Systemic

Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.

Aliases
5

FK228, FR901228, FR 901228, NSC 630176, Istodax

Signal depth
High

FDA label signal · 109 trials · 2189 PubMed results

Established

Romidepsin is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.

Romidepsin has 59 name-matched clinical trials (1 international) (highest phase: Phase 3) and 2189 PubMed-indexed publications and holds an FDA drug label. 25 trials have posted results.

🌍 1 international trial FAERS (approved drug): 785
Human data
Approved drug
Trial quality
Large RCT
Outcomes
Clinical outcomes
Replication
Meta-analysis
Literature
Top-tier journals

Re-checked nightly against the registries — tracked since 2026-11-17. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →


What is Romidepsin?

Romidepsin is a bicyclic depsipeptide natural product, not a conventional peptide built from a linear chain of amino acids. It was isolated from a broth culture of the soil bacterium Chromobacterium violaceum No. 968 and first described under the code FR901228 (later FK228), with the molecular formula C24H36N4O6S2 (Ueda et al., Journal of Antibiotics, 1994;47(3):301–310); the structure was reported in a companion paper (Shigematsu et al., Journal of Antibiotics, 1994;47(3):311–314). The US label gives a molecular weight of 540.71. The core is a 16-membered ring closed by an ester (the “depsi” linkage) and bridged by a disulfide bond, and its disulfide is reduced by glutathione on uptake into cells (VanderMolen et al., Journal of Antibiotics, 2011;64(8):525–531). Like daptomycin, it is a bacterial depsipeptide rather than a ribosomally made peptide. The literature often calls it simply “depsipeptide,” and the National Cancer Institute carried it as NSC 630176.

Clinically it is a class I-selective histone deacetylase (HDAC) inhibitor. The FDA approved it on November 5, 2009 as Istodax for cutaneous T-cell lymphoma (CTCL), granted accelerated approval for relapsed or refractory peripheral T-cell lymphoma (PTCL) on June 16, 2011, and removed that second indication in 2021 after the only randomized PTCL trial failed. It is a hospital-administered intravenous oncology drug.

How it works

  • A natural prodrug activated by intracellular reduction. FK228 itself is a weak HDAC inhibitor; reduction of its disulfide by cellular glutathione releases a free thiol that reaches the enzyme’s active site and interacts with the catalytic zinc. The reduced form inhibits HDAC1 and HDAC2 more strongly than HDAC4 or HDAC6 but is quickly inactivated in medium and serum, so the oxidized bicyclic form acts as a stable carrier switched on only after uptake into cells (Furumai et al., Cancer Research, 2002;62(17):4916–4921).
  • Histone hyperacetylation, cell-cycle arrest and apoptosis. FR901228 was identified as an HDAC inhibitor when a screen for microbial metabolites that activate the SV40 promoter picked it up alongside trichostatin A; despite no structural relationship to trichostatins, it blocked intracellular HDAC activity, caused acetylated histones to accumulate and arrested cells at both G1 and G2/M (Nakajima et al., Experimental Cell Research, 1998;241(1):126–133). The FDA label states that the mechanism of its antineoplastic effect has not been fully characterized.
  • Pharmacology that shapes its use. FR901228 was first noticed for reverting the transformed morphology of Ha-ras-transformed cells (Ueda et al., Journal of Antibiotics, 1994;47(3):301–310). In patients the label records a terminal half-life of about 3 hours, P-glycoprotein substrate status and accumulation in hepatocytes by an unknown active uptake process; co-administered rifampin, a CYP3A4 inducer that would be expected to lower exposure, instead raised romidepsin exposure by about 80%.

Research status

From soil isolate to NCI trials. FR901228 entered clinical development at the National Cancer Institute, where a phase I trial in advanced cancer was followed by a multi-institutional phase II trial in CTCL and PTCL (NCT00007345, started March 8, 2001). Among 71 CTCL patients with a median of four prior treatments the overall response rate was 34% (95% CI 23 to 46%) with a median response duration of 13.7 months (Piekarz et al., Journal of Clinical Oncology, 2009;27(32):5410–5417); among 45 evaluable PTCL patients it was 38% (95% CI 24 to 53%) with a median duration of 8.9 months (Piekarz et al., Blood, 2011;117(22):5827–5834).

Pivotal CTCL study (NCT00106431). An international single-arm phase II trial treated 96 patients with stage IB to IVA CTCL after at least one systemic therapy, 71% with advanced disease. The response rate was 34% (6 complete responses) with a median duration of 15 months, and 28 of 65 evaluable patients (43%) had a clinically meaningful reduction in pruritus (Whittaker et al., Journal of Clinical Oncology, 2010;28(29):4485–4491). The label pools this study with the NCI cohort as 167 CTCL patients treated in the US, Europe and Australia. The FDA approved Istodax on November 5, 2009 under NDA 022393 as a standard-review orphan drug.

Pivotal PTCL study (NCT00426764) and accelerated approval. A second single-arm phase II trial enrolled 131 patients with relapsed or refractory PTCL after a median of two prior therapies; the independent-review response rate was 25% (33 of 130), with 15% complete or unconfirmed complete responses and a median response duration of 17 months; the most common grade 3 or higher adverse events were thrombocytopenia (24%), neutropenia (20%) and infections (19%) (Coiffier et al., Journal of Clinical Oncology, 2012;30(6):631–636). With 22.3 months of median follow-up the median response duration reached 28 months (Coiffier et al., Journal of Hematology & Oncology, 2014;7:11). The FDA granted accelerated approval for PTCL after at least one prior therapy on June 16, 2011 (NDA 022393/S-004).

Ro-CHOP (NCT01796002): the randomized test that failed. The LYSA group’s phase III trial randomized 421 adults with untreated PTCL between January 2013 and December 2017 to six cycles of CHOP with or without romidepsin. Median progression-free survival was 12.0 versus 10.2 months (hazard ratio 0.81; P = 0.096) and overall survival 51.8 versus 42.9 months, neither significant, while grade 3 or 4 thrombocytopenia (50% versus 10%), neutropenia (49% versus 33%) and anemia (47% versus 17%) were far more frequent with romidepsin (Bachy et al., Journal of Clinical Oncology, 2022;40(3):242–251). The final analysis at a median follow-up of 6 years gave a progression-free survival hazard ratio of 0.79 (P = 0.054) and an overall survival hazard ratio of 0.88 (P = 0.324); only an exploratory follicular helper T-cell lymphoma subgroup favored Ro-CHOP, with median progression-free survival of 19.5 versus 10.6 months (Camus et al., Journal of Clinical Oncology, 2024;42(14):1612–1618).

Removal of the PTCL indication. Celgene submitted a supplemental application on June 17, 2021 to voluntarily remove the PTCL indication, and the FDA approved the revised labeling on July 30, 2021 (NDA 022393/S-017); the current label states that Istodax is not indicated or recommended for PTCL. A Federal Register notice published May 9, 2022 (87 FR 27644) formally withdrew the indication for Istodax and for the romidepsin injection under NDA 208574 at both holders’ request.

Regional decisions. In the European Union, an application for Istodax in PTCL drew a negative CHMP opinion on July 19, 2012, confirmed after re-examination on November 15, 2012, because the single-arm pivotal study could not establish a survival benefit; romidepsin has never been authorized in the EU. In Japan, Istodax Injection 10 mg (Celgene K.K.) was approved on July 3, 2017 as an orphan drug for relapsed or refractory PTCL on the basis of a 51-patient phase 1/2 study (NCT01456039), so the PTCL indication remains approved there.

Combination regimens in PTCL. A phase 2 trial of oral azacitidine plus romidepsin in 25 patients reported a 61% response rate with 48% complete responses, rising to 80% and 67% in the T-follicular helper phenotype (Falchi et al., Blood, 2021;137(16):2161–2170); a randomized phase IIB trial of that doublet against investigator’s choice in relapsed or refractory PTCL (NCT04747236) is recruiting with primary completion estimated for June 2, 2028. Romidepsin plus lenalidomide as initial treatment in 29 patients with a median age of 75 gave a 65.2% response rate with 26.1% complete responses among 23 evaluable (Ruan et al., Blood Advances, 2023;7(19):5771–5779). As of November 2026, ClinicalTrials.gov lists three recruiting trials that include romidepsin, all academic-sponsored.

HIV latency reversal. In six aviremic adults on antiretroviral therapy, romidepsin infusions made plasma HIV-1 RNA quantifiable in 5 of 6 (Søgaard et al., PLoS Pathogens, 2015;11(9):e1005142). A placebo-controlled study of 59 participants (NCT01933594) found no significant increase in viremia at any dose (McMahon et al., Journal of Infectious Diseases, 2021;224(4):648–656), and the ROADMAP trial with the antibody 3BNC117 in 22 participants did not meaningfully delay viral rebound after treatment interruption (Gruell et al., Lancet Microbe, 2022;3(3):e203–e214). No romidepsin HIV program is active.

Cardiac and infectious safety. Across 131 NCI trial patients, serial ECGs, troponins and imaging showed no cardiac toxicity, although electrolyte replacement criteria were met before 55% of 1,365 doses (Noonan et al., Clinical Cancer Research, 2013;19(11):3095–3104), and a formal ECG analysis found a maximum mean QTcF increase of 10.1 ms (Sager et al., Cancer Medicine, 2015;4(8):1178–1185). A case series documented reactivation of Epstein-Barr and hepatitis B viruses during HDAC inhibitor therapy (Ritchie et al., Haematologica, 2009;94(11):1618–1622).

Common dosage forms

  • Istodax for injection (NDA 022393). A single-dose vial of 10 mg romidepsin as a lyophilized powder, co-packaged with a vial of diluent, for intravenous infusion by oncology staff; Istodax Injection 10 mg is the same lyophilized presentation in Japan.
  • Generic lyophilized vials. 10 mg single-dose vials with diluent from several generic manufacturers, for intravenous infusion.
  • Ready-to-dilute solution, 5 mg/mL. A 27.5 mg/5.5 mL single-dose vial for intravenous infusion; the earlier 10 mg/2 mL and 27.5 mg/5.5 mL solution vials are discontinued.
  • No other presentation. No oral or compounded form exists.

Key considerations

  • Regulatory status. The FDA Approved status reflects the November 5, 2009 approval of Istodax (romidepsin) for injection under NDA 022393 for cutaneous T-cell lymphoma in adults who have received at least one prior systemic therapy. The June 16, 2011 accelerated approval for peripheral T-cell lymphoma was removed from the label on July 30, 2021 and formally withdrawn on May 9, 2022, so the US indication is CTCL only. Generic lyophilized vials and a ready-to-dilute solution are also approved.
  • An accelerated approval that did not confirm. The PTCL indication rested on a 25% single-arm response rate and was withdrawn once the only randomized trial added toxicity without a survival gain; later combination data are small and uncontrolled.
  • Toxicity is substantial and class-typical. Cytopenias, nausea, fatigue and infections dominate the trial data, viral reactivation has been fatal, and ST-T wave changes on ECG are common even though formal ECG studies found no meaningful QT prolongation.
  • A natural product and a prodrug, not a research peptide. Romidepsin is a bacterial bicyclic depsipeptide whose disulfide must be reduced inside cells to inhibit HDAC1 and HDAC2, and it has no footprint among research-market peptides. FK228, FR901228, NSC 630176, “depsipeptide” and Istodax are the same molecule; vorinostat and belinostat are distinct HDAC inhibitors, not aliases.
  • Outside oncology, the evidence is negative. Romidepsin reverses HIV-1 latency in vivo, but controlled trials showed no reservoir reduction or delay in viral rebound.